𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Radiofrequency ablation of head and neck tumors: Dramatic results from application of a new technology

✍ Scribed by Randall P. Owen; Thanjavur S. Ravikumar; Carl E. Silver; Jonathan Beitler; Scott Wadler; Jacqueline Bello


Book ID
102233307
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
228 KB
Volume
24
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

Radiofrequency ablation (RFA) is a new treatment modality used over the past decade predominantly in the treatment of unresectable liver tumors. We find no prior reported series on the use of RFA for malignant tumors of the head and neck.

Methods

Four patients with recurrent tongue tumors not amenable to standard surgical or radiation therapy were treated with RFA administered transorally, endoscopically, or percutaneously.

Results

There was no perioperative mortality. Significant palliation was achieved consisting of substantial reduction in tumor size and alleviation of tumor‐induced pain. One patient has survived for 8 months with no progression of tumor. Three patients had complications, including line sepsis, pneumonia, and enlargement of an orocutaneous fistula.

Conclusions

RFA was relatively straightforward to apply, achieved substantial palliation, and was associated with minimal perioperative morbidity and no mortality. It might easily be combined with other therapies such as chemotherapy, immunotherapy, or radiation. Further investigation is necessary and ongoing. Β© 2002 Wiley Periodicals, Inc. Head Neck 24: 754–758, 2002


πŸ“œ SIMILAR VOLUMES


Enhanced local dendritic cell activity a
✍ Koichiro Saito; Koji Araki; Nishant Reddy; Wei Guang; Bert W. O'Malley Jr; Daqin πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 443 KB

## Abstract ## Background. Radiofrequency ablation (RFA) is a minimally invasive tumor destruction technique and can provide the antigen source initiating tumor immunity. However, induced immune response is weak and requires additional immunotherapy for optimized RFA treatment against cancer. ##